Formulations and methods for treating acute cannabinoid overdose

Abstract

Described herein are uses of the CB1 inhibitors (e.g., antagonists, neutral antagonists, inverse agonists) and various methods of using and administering a CB1 inhibitor to a patient, especially patients showing symptoms of drug overdose or suspected of a drug overdose. Further described herein are uses wherein the CB1 inhibitor is ANEB-001. Further described herein are treatments with a CB1 inhibitor for THC or synthetic cannabinoid overdose.

What is claimed is: 
     
         1 . A method of using a pharmaceutical composition comprising a CB1 inhibitor, the method comprising administering to a patient an effective amount of the CB1 inhibitor and a pharmaceutically acceptable carrier or excipient, wherein the patient has a known or suspected acute drug overdose reaction, wherein the CB1 inhibitor has the structure: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or prodrug thereof. 
     
     
         2 . The method of  claim 1 , wherein the patient shows signs of an acute cannabinoid overdose. 
     
     
         3 . The method of  claim 2 , wherein the acute cannabinoid overdose is caused by a compound from the  Cannabis  genus. 
     
     
         4 . The method of  claim 2 , wherein the acute cannabinoid overdose is caused by a synthetic cannabinoid. 
     
     
         5 . The method of  claim 2 , wherein the acute cannabinoid overdose is caused by oral ingestion of cannabinoids or synthetic cannabinoids. 
     
     
         6 . The method of  claim 1 , wherein the patient shows signs of cannabinoid hyperemesis syndrome. 
     
     
         7 . The method of  claim 1 , wherein the method further comprises treatment for drug overdose prior to treatment with the CB1 inhibitor. 
     
     
         8 . The method of  claim 7 , wherein the prior treatment comprises one or more of administration of an opiate antagonist, activated charcoal, or emetic. 
     
     
         9 . The method of  claim 1 , wherein the method further comprises a diagnostic test prior to treatment with the CB1 inhibitor. 
     
     
         10 . The method of  claim 9 , wherein the diagnostic test is a blood test. 
     
     
         11 . The method of  claim 1 , wherein the patient has a cannabinoid plasma concentration of at least 50 μg/L. 
     
     
         12 . The method of  claim 1 , wherein the patient has a cannabinoid plasma concentration of 50 g/L to 300 μg/L. 
     
     
         13 . The method of  claim 1 , wherein the CB1 inhibitor is formulated as an oral, parenteral, intravenous (IV), intramuscular (IM), subcutaneous (SC), endotracheal, sublingual, buccal, intralingual, submental, transdermal, suppository, or intranasal administration. 
     
     
         14 . The method of  claim 13 , wherein the pharmaceutical composition is formulated for intranasal administration. 
     
     
         15 . The method of  claim 1 , wherein the dose of the CB1 inhibitor is 1 mg to 200 mg. 
     
     
         16 . The method of  claim 1 , wherein the dose of the CB1 inhibitor is 25 mg to 200 mg. 
     
     
         17 . The method of  claim 1 , wherein the dose of the CB1 inhibitor is 50 mg to 300 mg. 
     
     
         18 . The method of  claim 1 , wherein the pharmaceutical composition is formulated to deliver an effective dose of the CB1 inhibitor in no more than 10 min. 
     
     
         19 . The method of  claim 1 , wherein the pharmaceutical composition is formulated to deliver an effective dose of the CB1 inhibitor in no more than 5 min. 
     
     
         20 . The method of  claim 1 , wherein the CB1 inhibitor has the structure: